Analyst Price Targets — ANIP
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 16, 2026 8:11 pm | — | Canaccord Genuity | $91.00 | $81.92 | TheFly | ANI Pharmaceuticals initiated with a Hold at Canaccord |
| January 16, 2026 11:32 am | Vamil Divan | Guggenheim | $124.00 | $85.29 | StreetInsider | ANI Pharmaceuticals (ANIP) PT Raised to $124 at Guggenheim |
| October 9, 2025 1:23 pm | — | Truist Financial | $90.00 | $91.63 | TheFly | ANI Pharmaceuticals price target raised to $90 from $77 at Truist |
| September 17, 2025 2:17 pm | Brandon Folkes | H.C. Wainwright | $121.00 | $95.36 | TheFly | ANI Pharmaceuticals price target raised to $121 from $93 at H.C. Wainwright |
| September 8, 2025 11:46 am | Vamil Divan | Guggenheim | $114.00 | $95.20 | TheFly | ANI Pharmaceuticals price target raised to $114 from $86 at Guggenheim |
| August 8, 2025 3:00 pm | David Amsellem | Piper Sandler | $94.00 | $81.13 | TheFly | ANI Pharmaceuticals price target raised to $94 from $80 at Piper Sandler |
| March 5, 2025 1:58 pm | — | Guggenheim | $86.00 | $59.68 | TheFly | ANI Pharmaceuticals price target raised to $86 from $84 at Guggenheim |
| September 18, 2024 9:14 am | Gary Nachman | Raymond James | $83.00 | $61.23 | TheFly | ANI Pharmaceuticals price target raised to $83 from $81 at Raymond James |
| September 11, 2024 6:06 am | Les Sulewski | Truist Financial | $60.00 | $55.48 | TheFly | ANI Pharmaceuticals downgraded to Hold from Buy at Truist |
| June 26, 2024 6:36 am | Oren Livnat | H.C. Wainwright | $94.00 | $65.49 | StreetInsider | ANI Pharmaceuticals (ANIP) PT Raised to $94 at H.C. Wainwright |
Latest News for ANIP
PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Judge Sheldon K. Rennie, on July 16, 2026, denied ANI's post-trial motions for a new trial and judgment as a matter of law. ANI intends to appeal to the Delaware Supreme Court and continue to seek to recover the value of the assets it sold to CG Oncology under the 2010 Agreement…
ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported positive topline data from a Phase 4 trial of its fluocinolone acetonide intravitreal implant in chronic non-infectious uveitis, drawing on results from its open-label SYNCHRONICITY study, the company said. ANI Pharmaceuticals said the SYNCHRONICITY trial was a Phase 4, open-label, single-arm study of the fluocinolone acetonide intravitreal implant in patients with…
ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported positive topline data from a Phase 4 trial of its fluocinolone acetonide intravitreal implant in chronic...
PRINCETON, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced positive topline data from its Phase 4, open-label, single-arm SYNCHRONICITY clinical trial of Fluocinolone Acetonide Intravitreal Implant in patients with chronic non-infectious uveitis affecting the posterior segment of the eye (chronic NIU-PS).
The executive disposed of 3,313 shares on July 2, 2026, for a total transaction value of about $285,000. The transaction represented 2% of the insider's total direct equity holdings in the company.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ANIP.
U.S. House Trading
No House trades found for ANIP.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.